ConductScience.org, home

Paper22242561

Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.

Czock D and 2 others. Br J Clin Pharmacol, 2012. Cited by 20 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Papers, record 22242561. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22242561

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
PubMed
Journal
Br J Clin Pharmacol
PubMed
Year
2012
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
0.59
iCite
Revised in PubMed
2021-10-21
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Czock DDavid
2Keller FFrieder
3Seidling HMHanna M

Source PubMed

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
KidneyMajor topic
PeptidesMajor topic
Pharmaceutical PreparationsMajor topic
ProteinsMajor topic
Renal InsufficiencyMajor topic
Dose-Response Relationship, Drug
Half-Life
Humans
Metabolic Clearance Rate
Models, Theoretical
Molecular Weight

Source PubMed

References45

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116,554,449The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects.J Clin Pharmacol2006https://conductscience.org/library/papers/16554449PubMed
29,098,666Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.Drugs1997https://conductscience.org/library/papers/9098666PubMed
38,222,296Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects.Clin Endocrinol (Oxf)1993https://conductscience.org/library/papers/8222296PubMed
49,354,307Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency.Br J Clin Pharmacol1997https://conductscience.org/library/papers/9354307PubMed
515,373,927Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients.Br J Clin Pharmacol2004https://conductscience.org/library/papers/15373927PubMed
68,967,884The effects and pharmacokinetics of rhG-CSF in patients with chronic renal failure.Artif Organs1995https://conductscience.org/library/papers/8967884PubMed
716,259,772The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis.J Pharm Pharmacol2005https://conductscience.org/library/papers/16259772PubMed
818,807,251Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.Eur J Clin Pharmacol2009https://conductscience.org/library/papers/18807251PubMed
912,678,690Drug metabolism in chronic renal failure.Curr Drug Metab2003https://conductscience.org/library/papers/12678690PubMed
1010,541,299Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.J Am Soc Nephrol1999https://conductscience.org/library/papers/10541299PubMed
1112,844,139Pharmacokinetics of anakinra in subjects with different levels of renal function.Clin Pharmacol Ther2003https://conductscience.org/library/papers/12844139PubMed
1217,425,627Effect of renal impairment on the pharmacokinetics of exenatide.Br J Clin Pharmacol2007https://conductscience.org/library/papers/17425627PubMed
131,101,090Insulin and the kidney.Nephron1975https://conductscience.org/library/papers/1101090PubMed
149,848,789Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.J Am Soc Nephrol1998https://conductscience.org/library/papers/9848789PubMed
1512,753,429Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure.Pharmacol Toxicol2003https://conductscience.org/library/papers/12753429PubMed
1616,945,116Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration.Br J Clin Pharmacol2007https://conductscience.org/library/papers/16945116PubMed
1717,555,463Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency.Br J Clin Pharmacol2007https://conductscience.org/library/papers/17555463PubMed
1820,384,392CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.Clin Pharmacokinet2010https://conductscience.org/library/papers/20384392PubMed
199,336,364IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.J Clin Oncol1997https://conductscience.org/library/papers/9336364PubMed
2019,702,530Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.Curr Drug Metab2009https://conductscience.org/library/papers/19702530PubMed

See all 45 references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42,656,976Beyond complement: comprehensive assessment of factor XIII plasma dynamics and genetics in atypical hemolytic uremic syndrome.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/42656976PubMed
42,524,171Molecular Survival Strategies Against Kidney Filtration: Implications for Therapeutic Protein Engineering.Biophysica2026https://conductscience.org/library/papers/42524171PubMed
41,892,463Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country Analysis.Antibiotics (Basel)2026https://conductscience.org/library/papers/41892463PubMed
40,519,647A real-world study based on the FAERS database evaluating adverse drug reactions in three amphotericin B lipid formulations.J Pharm Policy Pract2025https://conductscience.org/library/papers/40519647PubMed
37,231,199Impact of Organ Impairment on the Pharmacokinetics of Therapeutic Peptides and Proteins.AAPS J2023https://conductscience.org/library/papers/37231199PubMed
36,588,717Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Front Pharmacol2022https://conductscience.org/library/papers/36588717PubMed
35,076,485Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted?Antibodies (Basel)2021https://conductscience.org/library/papers/35076485PubMed
34,698,086Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody-Drug Conjugates (ADCs).Antibodies (Basel)2021https://conductscience.org/library/papers/34698086PubMed
34,213,592The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer.Cancer Chemother Pharmacol2021https://conductscience.org/library/papers/34213592PubMed
31,544,862Factors Affecting the Pharmacology of Antibody-Drug Conjugates.Antibodies (Basel)2018https://conductscience.org/library/papers/31544862PubMed
31,544,809Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients.Antibodies (Basel)2019https://conductscience.org/library/papers/31544809PubMed
25,366,889Strategic approaches to optimizing peptide ADME properties.AAPS J2015https://conductscience.org/library/papers/25366889PubMed
23,187,965Pharmacokinetics of teduglutide in subjects with renal impairment.Eur J Clin Pharmacol2013https://conductscience.org/library/papers/23187965PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22242561

GET https://conductscience.org/api/papers/v1/22242561/references?page=2